Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

Good Sunday morning from Seattle . . . Our Online Travel Update for the week ending Friday, August 8, 2025, is below. For several weeks now, we’ve ...

Total Revenue Increased 16% Sequentially Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Co ...

CIBC names Kevin Li to lead its U.S. business as part of a leadership shuffle that comes ahead of Harry Culham becoming CEO ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Executives weighed in on the FHFA title waiver pilot, as well as M&A and Texas’ new title insurance pricing rules ...

The Canadian bank named Kevin Li the next CEO of its U.S. operations. Current U.S. CEO Shawn Beber will shift to a special adviser role in November before retiring next July.

Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Detailed price information for Verrica Pharmaceuticals Inc (VRCA-Q) from The Globe and Mail including charting and trades.

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million ...

OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) ("Star” or the ...